– USA, MA – Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Dr. Kathryn Boor (Ph.D.) to its Board of Directors, bringing distinct and invaluable experience to the board.
“We’re pleased to welcome two new board members whose participation will contribute to the realization of Sarepta’s strategic vision to create transformative therapies for patients with rare diseases,” said Board Chair, Dr. Kathleen Behren.
Dr. Kathleen Behren added, “Mr. Chambers’ appointment brings tremendous bioscience and entrepreneurial leadership, along with deep expertise in areas of fundamental importance to genetic medicine innovators. Dr. Boor, in addition to her scientific and academic credentials, is an expert in the environment, sustainability, and governance, a topic of significant importance to Sarepta,” said Doug Ingram, Sarepta’s president and chief executive officer. “These new appointments add to the diversity of experience and perspective on our Board, providing outstanding leadership as we work with the greatest urgency to bring innovative genetic medicines to patients.”
About Michael Chambers
Mr. Chambers co-founded Aldevron, based in Fargo, N.D., in 1998, and served as CEO for more than 20 years before serving as Executive Chairman of the Board until 2021 when Aldevron was acquired for $9.6 billion. As a founder, Michael Chambers oversaw the growth of Aldevron into a world-class service organization, specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe. Michael Chambers currently serves on the Board of Directors at Calviri, Inc.
In 2018, Michael Chambers was named one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs.
He earned his bachelor’s degree in biotechnology, microbiology, and chemistry from North Dakota State University.
About Dr. Kathryn Boor
Dr. Kathryn Boor is the Dean of the Graduate School and Vice-Provost for Graduate Education at Cornell University. Previously, Dr. Boor served as the Ronald P. Lynch Dean of the College of Agriculture and Life Sciences at Cornell.
She earned a bachelor’s degree in food science from Cornell University, a master’s degree from the University of Wisconsin, and a Ph.D. in microbiology from the University of California, Davis. She joined the Cornell Food Science department as an assistant professor in 1994, became its first tenured female faculty member in 2000, and led as department chair from 2007-to 2010.
Dr. Boor serves on the Board of Directors for Seneca Foods Corporation, International Flavors and Fragrances, the United States-Israel Binational Agricultural Research and Development Fund, and the Foundation for Food and Agriculture Research. She serves on the Science Board for the US Food and Drug Administration and the New York State Southern Tier Regional Economic Development Council.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.
For more information: https://www.sarepta.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
